Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients

Circulation Journal

Volumn 76, Issue 3, 2012, Pages 712-720

  Kataoka, Yu ^a   Yasuda, Satoshi ^b   Miyamoto, Yoshihiro ^a   Sase, Kazuhiro ^c   Kosuge, Masami ^d   Kimura, Kazuo ^d   Yoshimasa, Yasunao ^a   Miyazaki, Shunichi ^e  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery atherosclerosis; Diabetes mellitus; Impaired glucose tolerance; Postprandial hyperglycemia

Indexed keywords

ADIPONECTIN; ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOLECULAR WEIGHT ADIPONECTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VOGLIBOSE;

ABDOMINAL DISEASE; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC INDEX; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; CORONARY ARTERY DISEASE; CYCLOHEXANES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; MIDDLE AGED; PHENYLALANINE;

EID: 84857567374     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1011     Document Type: Article

References (37)

1. Fox CS, Coady S, Sorlie PD, D'Agostino RB Sr, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 2007; 115: 1544-1550.
2. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemic and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473-2479.
3. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
7. Gavin JR 3rd. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001; 88: 4H-8H.
8. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of betacell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.
9. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92: 18J-26J.
10. Satoh H, Terada H, Uehara A, Katoh H, Matsunaga M, Yamazaki K, et al. Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus. Heart 2005; 91: 731-736.
11. Lim S, Despres JP, Koh KK. Prevention of atherosclerosis in overweight/ obese patients: In need of novel multi-targeted approaches. Circ J 2011; 75: 1019-1027.
12. Kataoka Y, Yasuda S, Morii I, Otsuka Y, Kawamura A, Miyazaki S. Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance. Diabetes Care 2005; 28: 2217-2222.
13. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-467.
14. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 115: 539-553.
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
17. Kataoka Y, Yasuda S, Morii I, Kawamura A, Miyazaki S. Improved long-term prognosis of elderly women in the era of sirolimus-eluting stents. Circ J 2009; 73: 1219-1227.
18. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000; 11: 561-570.
19. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
21. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.
22. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-1476.
23. Gao HW, Xie C, Wang HN, Lin YJ, Hong TP. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin 2007; 28: 534-539.
24. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998; 21: 256-260.
25. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova- Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
26. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280: 2001-2007.
27. Haller H. Postprandial glucose and vascular disease. Diabet Med 1997; 14: S50-S56.
28. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002; 106: 2067-2072.
29. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-2300.
30. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007; 99: 6B-14B.
31. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
32. Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006; 113: 2936-2942.
33. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
34. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
35. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006; 84: 276-294.
36. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263: 256-273.
37. Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-2270.